APA (7th ed.) Citation

S, P., A, L., H, H., M, G., F, L., V, G., . . . Dktk-Rog, O. B. O. T. (2022). A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers, 14(12), . https://doi.org/10.3390/cancers14123031

Chicago Style (17th ed.) Citation

S, Patil, et al. "A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients Amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT." Cancers 14, no. 12 (2022). https://doi.org/10.3390/cancers14123031.

MLA (9th ed.) Citation

S, Patil, et al. "A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients Amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT." Cancers, vol. 14, no. 12, 2022, https://doi.org/10.3390/cancers14123031.